Spinraza, the gene therapy medication, also provides significant improvements in cases with the next most severe form of neuromuscular disease, spinal muscular atrophy (SMA), which afflicts children from 6 to 18 months of age.
from Top Health News -- ScienceDaily http://ift.tt/2GM4vIf
No comments:
Post a Comment